DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515167-56-00

Acronym

GESIDA 11720

Enrollment

555

Registered

2024-09-05

Start date

2021-06-22

Completion date

2025-03-13

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL (FDA Snapshot, 4% non-inferiority margin).

Interventions

DRUGBiktarvy 50 mg/200 mg/25 mg film-coated tablets

DRUGDovato 50 mg/300 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL (FDA Snapshot, 4% non-inferiority margin).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026